RecruitingPhase 4NCT06367855

Efficacy and Safety of Preemptive Intravenous Dexamethasone in MIS-TLIF


Sponsor

Potsawat Surabotsopon

Enrollment

60 participants

Start Date

May 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Researchers are considering Dexamethasone as preemptive medication before minimally invasive spine fusion surgery to minimize postoperative back pain with minimal side effects, aiming to enhance the effectiveness of surgery and improve patient outcomes.


Eligibility

Min Age: 50 YearsMax Age: 80 Years

Inclusion Criteria2

  • Age range: 50-80 years old.
  • Undergoing MIS TLIF surgery at 1-2 spinal levels.

Exclusion Criteria4

  • Previously undergone spine surgery.
  • HbA1C greater than or equal to 7.5 mg%
  • Allergic to all types of experimental medication.
  • History of using systemic steroids.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDexamethasone

long-acting corticosteroid IV route

DRUGNormal saline

normal saline


Locations(1)

Thammasat university hospital

Pathum Thani, Changwat Pathum Thani, Thailand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06367855


Related Trials